A detailed history of Parallel Advisors, LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 16,457 shares of INZY stock, worth $49,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,457
Previous 16,033 2.64%
Holding current value
$49,700
Previous $71,000 21.13%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.31 - $6.0 $1,827 - $2,544
424 Added 2.64%
16,457 $86,000
Q4 2023

Feb 09, 2024

BUY
$2.71 - $4.5 $1,100 - $1,827
406 Added 2.6%
16,033 $68,000
Q3 2023

May 20, 2024

BUY
$4.09 - $7.0 $818 - $1,400
200 Added 1.3%
15,627 $65,000
Q3 2023

Nov 13, 2023

BUY
$4.09 - $7.0 $818 - $1,400
200 Added 1.3%
15,627 $65,000
Q2 2023

May 20, 2024

SELL
$4.93 - $6.74 $21,889 - $29,925
-4,440 Reduced 22.35%
15,427 $85,000
Q2 2023

Aug 04, 2023

SELL
$4.93 - $6.74 $21,889 - $29,925
-4,440 Reduced 22.35%
15,427 $85,000
Q1 2023

May 20, 2024

BUY
$1.3 - $5.73 $4,984 - $21,968
3,834 Added 23.91%
19,867 $113,000
Q4 2022

Feb 03, 2023

BUY
$1.05 - $2.82 $20,860 - $56,024
19,867 New
19,867 $20,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $121M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.